On day 21, the increase of tumor volume of mice treated by RT with targeted radiosensitizer was suppressed to 33.1% ± 17.1%.
CACPR mice showed reduced freezing to context, not to cued and CACPR mice treated by 4-PCO showed more freezing to context, significantly.
Histology performed in 24 h showed decreased disruption of lung structures in mice treated by WT-MSCs in comparison to PBS (Table 1), even though this difference did not reach statistical significance.
WT-MSCs administered 1 h after acid aspiration attenuated the evolution of fibrosis, as demonstrated by lower collagen deposition (OH-Pro assay) in 2 weeks (Fig. 4a) in comparison to mice treated by PBS.
The average lifespan of the mice treated by the above combined therapy is beyond 40 days, which are ∼2.6 times longer than that (15 days) observed from the anticancer drug doxorubicin-treated group.
Similarly, micro-CT scan analysis showed that the extent of lung collapse significantly decreased between 1 and 24 h in WT mice treated by WT-MSCs (p = 0.01), likely indicating decreased superimposed weight from reduced lung edema (Table 1 and Fig. 3), but not in those treated by PBS.
The population of NK cells was significantly increased in mice treated by rAAV-/rAdv-hTERTC27 viral cocktail (43.4%) compared with mice treated by rAAV-/rAdv-EGFP (12.2%) or PBS (17.7%) (Fig. 2A and 2C).
As compared with epirubicin treated group, both the tumor sizes and tumor weights in mice treated by epirubicin plus SK1-I were dramatically reduced (Figures 3A and 3B).
Similarly, no significant difference in metastasis of parental RMS14 cells was found in mice treated by either TSA or VPA (Figure 5D, E).
Splenocytes collected from mice treated by epicutaneous CII after induction of CCIA also exhibited reduced dose-dependent T cell proliferation to CII stimulation compared to T cells from sham-treated CCIA mice (Figure 8A).
In cocultures, cells from mice treated by epicutaneously immunization were able to actively inhibit CII-specific proliferation and IFN-γ release by effector cells, suggesting an active regulatory mechanism.
